Zentalis IPO: A Strong Biotech IPO In The Current Market [Seeking Alpha]
Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
Company Research
Source: Seeking Alpha
SummaryBiotech pharmaceutical company Zentalis Pharmaceuticals has launched a successful IPO that values the company at over $730 million.Zentalis has developed four treatments to handle different kind of cancers, and has multiple partners including Pfizer.The market for cancer research will continue to grow rapidly as the global population ages, though there Zentalis faces complications from the coronavirus epidemic.Zentalis is in a strong financial position, with enough cash on hand to stay operational until 2022.Biotech IPOs are especially risky under the current economic circumstances, but Zentalis may be good enough to take a chance on.The coronavirus may have gripped the world’s attention, but other medical maladies still exist, and medical researchers are working on those as well as the coronavirus. Zentalis Pharmaceuticals (NASDAQ:ZNTLRenaissance CapitalZentalis is the second U.S. IPO to launch since the coronavirus pandemic has truly begun, following WiMi Hologram (NASDAQ:WIM
Show less
Read more
Impact Snapshot
Event Time:
ZNTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZNTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZNTL alerts
High impacting Zentalis Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ZNTL
News
- Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law FirmGlobeNewswire
- Umoja Biopharma Appoints Scott Myers as Chairman of its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its price target lowered by analysts at Guggenheim from $12.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of AzenosertibGlobeNewswire
ZNTL
Earnings
- 11/12/24 - Beat
ZNTL
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form 4
- 11/13/24 - Form 3
- ZNTL's page on the SEC website